Biopharma Dealmakers – Merus Profile

Battling cancer with bispecific antibodies
Merus is using its Biclonics technology platform to generate differentiated therapeutics in the form of fulllength human IgG bispecific antibodies designed to recruit the immune system to eliminate cancer cells.

This article was published in the June 2017 issue of BioPharma Dealmakers. The full issue can be read here.